| Group 1 | Group 2 | Group 3 |
---|---|---|---|
TG/HDL-C < 1.60 (N = 224) | 1.60 ≤ TG/HDL-C < 2.97 (N = 221) | TG/HDL-C ≥ 2.97 (N = 311) | |
Composite endpoint of renal function decline | |||
  Number of cases, n (%) | 35 (15.62) | 46 (20.81) | 69 (22.19) |
  Unadjusted, OR (95 % CI) | ref. | 1.42 (0.87, 2.31) | 1.54 (0.98, 2.41) |
 P |  | 0.16 | 0.06 |
  Age and gender adjusted, OR (95 % CI) | ref. | 1.46 (0.89, 2.38) | 1.69 (1.07, 2.68) |
 P |  | 0.13 | 0.02 |
  Multivariable-adjusted, OR (95 % CI) | ref. | 1.32 (0.75, 2.30) | 1.90 (1.21, 3.23) |
 P |  | 0.33 | 0.02 |
Decline in eGFR category | |||
  Number of cases, n (%) | 33 (14.73) | 42 (19.00) | 62 (19.94) |
  Unadjusted, OR (95 % CI) | ref. | 1.36 (0.82, 2.24) | 1.44 (0.91, 2.29) |
 P |  | 0.23 | 0.12 |
  Age and gender adjusted, OR (95 % CI) | ref. | 1.39 (0.84, 2.30) | 1.57 (0.98, 2.51) |
 P |  | 0.20 | 0.06 |
  Multivariable-adjusted, OR (95 % CI) | ref. | 1.33 (0.76, 2.32) | 1.89 (1.12, 3.21) |
 P |  | 0.32 | 0.02 |
Rapid decline in eGFR | |||
  Number of cases, n (%) | 24 (10.71) | 32 (14.48) | 47 (15.11) |
  Unadjusted, OR (95 % CI) | ref. | 1.41 (0.80, 2.48) | 1.48 (0.88, 2.51) |
 P |  | 0.23 | 0.14 |
  Age and gender adjusted, OR (95 % CI) | ref. | 1.43 (0.81, 2.53) | 1.57 (0.92, 2.67) |
 P |  | 0.22 | 0.10 |
  Multivariable-adjusted, OR (95 % CI) | ref. | 1.24 (0.30, 5.13) | 3.28 (0.97, 11.10) |
 P |  | 0.16 | 0.06 |
> 30 % decline in eGFR | |||
  Number of cases, n (%) | 9 (4.02) | 15 (6.79) | 23 (7.40) |
  Unadjusted, OR (95 % CI) | ref. | 1.74 (0.74, 4.06) | 1.91 (0.87, 4.21) |
 P |  | 0.20 | 0.11 |
  Age and gender adjusted, OR (95 % CI) | ref. | 1.74 (0.74, 4.06) | 1.89 (0.86, 4.19) |
 P |  | 0.20 | 0.12 |
  Multivariable-adjusted, OR (95 % CI) | ref. | 1.80 (0.70, 4.60) | 2.56 (1.05, 6.38) |
 P |  | 0.22 | 0.04 |